Product details

Drug development and discovery had long been an intricate and lengthy process with a very low success rate. This happened to be a key factor leading companies to collaborate cutting across disciplines to share the burden of cost as well as the other burdens. Eventually, joining forces became an order of the day and pharma-tech collaborations surfaced like never before. In once such instance, global pharma company H Lundbeck A/S (Lundbeck), which specialised in brain diseases partnered with Iambic Therapeutics (Iambic), the company known for its cutting-edge 'AI-driven platform' to pre-empt the most challenging design problems pertaining to drug discovery and address patients' unmet need. While both the companies were quite upbeat about their strategic AI-induced drug discovery partnership, they were likely to face multiple challenges including competition from the likes of pharma giant Pfizer, which had also made substantial headway with similar collaborative venture. Could the Lundbeck-Iambic partnership thrive in its business even amidst obvious challenges underlying drug discovery in a competitive landscape?